{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T15:34:26Z","timestamp":1764257666619,"version":"3.46.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jbspin.2025.105935","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T02:42:44Z","timestamp":1750473764000},"page":"105935","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["IL-6: A new target in crystal-induced arthritides\u00a0\u2013\u00a0A narrative review"],"prefix":"10.1016","volume":"92","author":[{"given":"Augustin","family":"Latourte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristan","family":"Pascart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Richette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jbspin.2025.105935_bib0300","doi-asserted-by":"crossref","first-page":"e791","DOI":"10.1016\/S2665-9913(24)00122-X","article-title":"Calcium pyrophosphate deposition disease","volume":"6","author":"Pascart","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"10287","key":"10.1016\/j.jbspin.2025.105935_bib0305","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","article-title":"Gout","volume":"397","author":"Dalbeth","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jbspin.2025.105935_bib0310","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1016\/S2665-9913(24)00117-6","article-title":"Global, regional, and national burden of gout, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021","volume":"6","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"10","key":"10.1016\/j.jbspin.2025.105935_bib0315","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","article-title":"2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"74","author":"Neogi","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.jbspin.2025.105935_bib0320","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1136\/ard-2023-224575","article-title":"The 2023 ACR\/EULAR classification criteria for calcium pyrophosphate deposition disease","volume":"82","author":"Abhishek","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105935_bib0325","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/art.24185","article-title":"Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout","volume":"60","author":"Martin","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"7081","key":"10.1016\/j.jbspin.2025.105935_bib0330","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jbspin.2025.105935_bib0335","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3390\/gucdd2030017","article-title":"Gout basic research: 2023 in review","volume":"2","author":"Muntiu","year":"2024","journal-title":"Gout Urate Cryst Depos Dis"},{"issue":"2","key":"10.1016\/j.jbspin.2025.105935_bib0340","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/art.30147","article-title":"Octacalcium phosphate crystals induce inflammation in vivo through interleukin-1 but independent of the NLRP3 inflammasome in mice","volume":"63","author":"Narayan","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.jbspin.2025.105935_bib0345","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/anr.1780321114","article-title":"Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes","volume":"32","author":"Guerne","year":"1989","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2025.105935_bib0350","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.3389\/fimmu.2018.02248","article-title":"Inflammatory potential of four different phases of calcium pyrophosphate relies on NF-kappaB activation and MAPK pathways","volume":"9","author":"Campillo-Gimenez","year":"2018","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.jbspin.2025.105935_bib0355","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/ard-2023-225305","article-title":"Systemic inflammatory cytokine profiles in patients with gout during flare, intercritical and treat-to-target phases: TNFSF14 as new biomarker","volume":"83","author":"Ea","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.jbspin.2025.105935_bib0360","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1002\/art.39318","article-title":"Gout is a chronic inflammatory disease in which high levels of interleukin-8 (CXCL8), myeloid-related protein 8\/myeloid-related protein 14 complex, and an altered proteome are associated with diabetes mellitus and cardiovascular disease","volume":"67","author":"Kienhorst","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.jbspin.2025.105935_bib0365","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/annrheumdis-2014-206564","article-title":"Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra","volume":"75","author":"Crisan","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jbspin.2025.105935_bib0370","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3390\/gucdd2040023","article-title":"Epigenomic reprogramming in gout","volume":"2","author":"Straton","year":"2024","journal-title":"Gout Urate Cryst Depos Dis"},{"key":"10.1016\/j.jbspin.2025.105935_bib0375","first-page":"2","article-title":"Calcium pyrophosphate and basic calcium phosphate crystal arthritis: 2023 in review","volume":"2024","author":"Latourte","year":"2024","journal-title":"Gout Urate Cryst Depos Dis"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105935_bib0380","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.jbspin.2025.105935_bib0385","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.jbspin.2025.105935_bib0390","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jbspin.2020.05.001","article-title":"2020 recommendations from the French Society of Rheumatology for the management of gout: management of acute flares","volume":"87","author":"Latourte","year":"2020","journal-title":"Joint Bone Spine"},{"issue":"2","key":"10.1016\/j.jbspin.2025.105935_bib0395","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/annrheumdis-2019-216154","article-title":"Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care","volume":"79","author":"Roddy","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.jbspin.2025.105935_bib0400","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1016\/S2665-9913(23)00165-0","article-title":"Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial","volume":"5","author":"Pascart","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"10.1016\/j.jbspin.2025.105935_bib0405","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.jbspin.2025.105935_bib0410","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41584-021-00725-9","article-title":"Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care","volume":"18","author":"Choi","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.jbspin.2025.105935_bib0415","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/acr.23160","article-title":"Calcium pyrophosphate deposition disease and associated medical comorbidities: a national cross-sectional study of US veterans","volume":"69","author":"Kleiber Balderrama","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.jbspin.2025.105935_bib0420","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1001\/jama.2022.11390","article-title":"Association between gout flare and subsequent cardiovascular events among patients with gout","volume":"328","author":"Cipolletta","year":"2022","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jbspin.2025.105935_bib0425","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1136\/annrheumdis-2022-222387","article-title":"Risk of cardiovascular events in patients having had acute calcium pyrophosphate crystal arthritis","volume":"81","author":"Tedeschi","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jbspin.2025.105935_bib0430","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/art.42986","article-title":"Short-term risk of cardiovascular events in people newly diagnosed with gout","volume":"77","author":"Cipolletta","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105935_bib0435","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13075-023-03098-4","article-title":"Interleukin-1beta inhibitors for the management of acute gout flares: a systematic literature review","volume":"25","author":"Schlesinger","year":"2023","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.jbspin.2025.105935_bib0440","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar3297","article-title":"Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study","volume":"13","author":"Schlesinger","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.jbspin.2025.105935_bib0445","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/ard.2010.144063","article-title":"Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study","volume":"70","author":"Schlesinger","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.jbspin.2025.105935_bib0450","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105935_bib0455","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/ar4159","article-title":"Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator","volume":"15","author":"Terkeltaub","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.jbspin.2025.105935_bib0460","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/art.41699","article-title":"A randomized, phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares","volume":"73","author":"Saag","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.jbspin.2025.105935_bib0465","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/rheumatology\/key402","article-title":"Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial","volume":"58","author":"Janssen","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.jbspin.2025.105935_bib0470","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jbspin.2018.03.015","article-title":"Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: a multicentre, retrospective study","volume":"85","author":"Loustau","year":"2018","journal-title":"Joint Bone Spine"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105935_bib0475","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0009-9236(03)00094-8","article-title":"Pharmacokinetics of anakinra in subjects with different levels of renal function","volume":"74","author":"Yang","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jbspin.2025.105935_bib0480","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jbspin.2012.01.010","article-title":"Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis","volume":"79","author":"Molto","year":"2012","journal-title":"Joint Bone Spine"},{"issue":"6","key":"10.1016\/j.jbspin.2025.105935_bib0485","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/RHU.0b013e31826149a2","article-title":"Interleukin 1beta blockade improves signs and symptoms of chronic calcium pyrophosphate crystal arthritis resistant to treatment","volume":"18","author":"Diamantopoulos","year":"2012","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.jbspin.2025.105935_bib0490","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jbspin.2012.07.018","article-title":"Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature","volume":"80","author":"Ottaviani","year":"2013","journal-title":"Joint Bone Spine"},{"issue":"2","key":"10.1016\/j.jbspin.2025.105935_bib0495","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10067-018-4272-2","article-title":"Efficacy and tolerance of anakinra in acute calcium pyrophosphate crystal arthritis: a retrospective study of 33 cases","volume":"38","author":"Thomas","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.jbspin.2025.105935_bib0500","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3899\/jrheum.181018","article-title":"Use of anakinra in hospitalized patients with crystal-associated arthritis","volume":"46","author":"Liew","year":"2019","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.jbspin.2025.105935_bib0505","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1007\/s10067-023-06573-0","article-title":"A single-centre retrospective case series of Anakinra for incident calcium pyrophosphate deposition disease","volume":"42","author":"Lian","year":"2023","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.jbspin.2025.105935_bib0510","doi-asserted-by":"crossref","first-page":"105088","DOI":"10.1016\/j.jbspin.2020.105088","article-title":"Anakinra compared to prednisone in the treatment of acute CPPD crystal arthritis: a randomized controlled double-blinded pilot study","volume":"88","author":"Dumusc","year":"2021","journal-title":"Joint Bone Spine"},{"issue":"12","key":"10.1016\/j.jbspin.2025.105935_bib0515","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1093\/rheumatology\/kez203","article-title":"Difficult-to-treat gout flares: eligibility for interleukin-1 inhibition in private practice is uncommon according to current EMA approval","volume":"58","author":"Pascart","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2025.105935_bib0520","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00003086-198804000-00023","article-title":"Clinical features of pseudogout attack. A survey of 50 cases","volume":"229","author":"Masuda","year":"1988","journal-title":"Clin Orthop Relat Res"},{"issue":"suppl 9","key":"10.1016\/j.jbspin.2025.105935_bib0525","article-title":"Macrophage intracellular fates of monosodium urate and calcium pyrophosphate crystals: phagocytosism exchanged\/expulsion and dissolution of crystals [abstract]","volume":"76","author":"Leroy","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.jbspin.2025.105935_bib0530","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1093\/rheumatology\/keab383","article-title":"Efficacy of subcutaneous tocilizumab in a patient with severe gout refractory to anakinra","volume":"60","author":"Calvo-Aranda","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.jbspin.2025.105935_bib0535","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.reuma.2012.06.009","article-title":"Tocilizumab in a patient with tophaceous gout resistant to treatment","volume":"9","author":"Pinto","year":"2013","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.jbspin.2025.105935_bib0540","article-title":"Tocilizumab improved clinical symptoms of a patient with systemic tophaceous gout who had symmetric polyarthritis and fever: an alternative treatment by blockade of interleukin-6 signaling","volume":"2","author":"Mokuda","year":"2014","journal-title":"SAGE Open Med Case Rep"},{"issue":"3","key":"10.1016\/j.jbspin.2025.105935_bib0545","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbspin.2017.04.008","article-title":"Interleukin-6 pathway blockade as an option for managing refractory cases of crystal arthritis: two cases report","volume":"85","author":"Quilis","year":"2018","journal-title":"Joint Bone Spine"},{"issue":"8","key":"10.1016\/j.jbspin.2025.105935_bib0550","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/annrheumdis-2020-217188","article-title":"Tocilizumab in symptomatic calcium pyrophosphate deposition disease: a pilot study","volume":"79","author":"Latourte","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jbspin.2025.105935_bib0555","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/rheumatology\/kead228","article-title":"Retention, safety and efficacy of off-label conventional treatments and biologics for chronic calcium pyrophosphate crystal inflammatory arthritis","volume":"63","author":"Damart","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"suppl 9","key":"10.1016\/j.jbspin.2025.105935_bib0560","article-title":"Efficacy and safety of tocilizumab in the treatment of chronic inflammatory forms of CPPD: retrospective study of 55 cases [abstract]","volume":"76","author":"Carrabin","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.jbspin.2025.105935_bib0565","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jama.2022.15459","article-title":"Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial","volume":"328","author":"Devauchelle-Pensec","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105935_bib0570","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jbspin.2014.07.010","article-title":"Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis","volume":"82","author":"Pers","year":"2015","journal-title":"Joint Bone Spine"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105935_bib0575","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/gucdd2010005","article-title":"A new era for calcium pyrophosphate deposition disease research: the first-ever calcium pyrophosphate deposition disease classification criteria and considerations for measuring outcomes in calcium pyrophosphate deposition disease","volume":"2","author":"Tedeschi","year":"2024","journal-title":"Gout Urate Cryst Depos Dis"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105935_bib0580","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.jbspin.2025.105935_bib0585","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S2665-9913(20)30065-5","article-title":"Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial","volume":"2","author":"Kluck","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"10.1016\/j.jbspin.2025.105935_bib0590","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11926-023-01128-3","article-title":"Pipeline therapies for gout","volume":"26","author":"Yip","year":"2024","journal-title":"Curr Rheumatol Rep"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X25000971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X25000971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T15:30:17Z","timestamp":1764257417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X25000971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1297319X25000971"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2025.105935","relation":{},"ISSN":["1297-319X"],"issn-type":[{"type":"print","value":"1297-319X"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-6: A new target in crystal-induced arthritides\u00a0\u2013\u00a0A narrative review","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2025.105935","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Fran\u00e7aise de Rhumatologie.","name":"copyright","label":"Copyright"}],"article-number":"105935"}}